Visual field constriction in 91 Finnish children treated with vigabatrin

Epilepsia

Volumn 43, Issue 7, 2002, Pages 748-756

  Vanhatalo, Sampsa ^a,r   Nousiainen, Iiris ^b   Eriksson, Kai ^c   Rantala, Heikki ^d   Vainionpää, Leena ^d   Mustonen, Kirsi ^e   Äärimaa, Tuula ^f   Alen, Reija ^g   Aine, Marjo Riitta ^h   Byring, Roger ⁱ   Hirvasniemi, Aune ^j   Nuutila, Auli ^k   Walden, Tiina ^l   Ritanen Mohammed, Ulla Maija ^m   Karttunen Lewandowski, Pirkko ⁿ   Pohjola, Leena Maria ^o   Kaksonen, Satu ^p   Jurvelin, Pekka ^q   Granström, Marja Liisa ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF OULU   (Finland)

^e NORTH KARELIA CENTRAL HOSPITAL   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^h LAPLAND CENTRAL HOSPITAL   (Finland)

ⁱ VAASA CENTRAL HOSPITAL   (Finland)

^j KAINUU CENTRAL HOSPITAL   (Finland)

^k SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

^l KYMENLAAKSO CENTRAL HOSPITAL   (Finland)

^m PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

ⁿ MIKKELI CENTRAL HOSPITAL   (Finland)

^o SOUTH KARELIA CENTRAL HOSPITAL   (Finland)

^p District Hospital of Western Nyland   (Finland)

^q Lansi Pohja Central Hospital   (Finland)

^r UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

Antiepileptic drug; Pediatric epilepsy; Side effect; Vigabatrin; Visual field

Indexed keywords

VIGABATRIN;

ARTICLE; CHILD; COGNITION; DISEASE PREDISPOSITION; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEURORADIOLOGY; PERIMETRY; PRIORITY JOURNAL; VISUAL FIELD DEFECT;

ADOLESCENT; AGE FACTORS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; FINLAND; HUMANS; MALE; PERIMETRY; PREVALENCE; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 18444382320     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2002.17801.x     Document Type: Article

References (46)

1. Vigabatrin
2. The role of vigabatrin in childhood seizure disorders: Results from a clinical audit
3. The influence of established and new antiepileptic drugs on visual perception, 1: A placebo-controlled, double-blind, single-dose study in healthy volunteers
4. Managing pediatric epilepsy syndromes with new antiepileptic drugs
5. Effect of long-term vigabatrin administration on the immature rat brain
6. The potential for vigabatrin-induced intramyelinic edema in humans
7. Vigabatrin (gamma-vinyl-GABA): Neuropathologic evaluation in five patients
8. A study of the effects of vigabatrin on the central nervous system and retina of Sprague-Dawley and Lister-hooded rats
9. Visual field constriction: Accumulation of vigabatrin but not tiagabine in the retina
10. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects
11. Characteristic of a unique visual field defect attributed to vigabatrin
12. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication
13. Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings
14. Vigabatrin-associated retinal cone system dysfunction: Electroretinogram and ophthalmologic findings
15. Visual field defects associated with vigabatrin therapy
16. Symptomatic and asymptomatic visual loss in patients taking vigabatrin
17. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin
18. Visual field loss associated with vigabatrin: Quantification and relation to dosage
19. Visual field defects with vigabatrin: Epidemiology and therapeutic implications
20. Visual field constriction in children treated with vigabatrin
21. Visual field constriction in children with epilepsy on vigabatrin treatment
22. Visual impairment in children with epilepsy treated with vigabatrin
23. Visual field constriction is not limited to children treated with vigabatrin
24. Visual field defects associated with vigabatrin monotherapy in children
25. Reversed visual field constriction in children after vigabatrin withdrawal: True retinal recovery or improved test performance only?
26. Vigabatrin-associated visual field defects in children
27. Care must be taken in interpretation of visual field tests in children
28. Vigabatrin and visual field defects in children with epilepsy: Guidelines and practical recommendations
29. Proposal for revised classification of epilepsies and epileptic syndromes
30. Distance and near visual acuity, contrast sensitivity, and visual fields of 10-year-old children
31. Visual fields in 4- to 10-year-old children using Goldmann and double-arc perimeters
32. The feasibility of short automated static perimetry in children
33. Electroretinographic changes are not associated with loss of visual function in pediatric epileptic patients following treatment with vigabatrin
34. Epilepsy surgery, visual fields, and driving: A study of the visual field criteria for driving in patients after temporal lobe epilepsy surgery with a comparison of Goldmann and Esterman perimetry
35. A controlled study of vigabatrin and visual abnormalities
36. Recovery of visual field constriction following discontinuation of vigabatrin
37. Visual function loss from vigabatrin: Effect of stopping the drug
38. Infantile spasms and vigabatrin: Visual field defects may be permanent
39. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms
40. Development of excitatory and inhibitory postsynaptic potentials in the rat neocortex
41. The K+/Cl-co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation
42. GABAA, NMDA and AMPA receptors: A developmentally regulated menage a trois
43. Separating the retinal electrophysiologic effects of vigabatrin: Treatment versus field loss
44. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction
45. Outer retinal dysfunction in patients treated with vigabatrin
46. Is the devil we know the lesser of two evils?